Menu Search
Equities

Cardiol Therapeutics Inc

CRDL:NAQ

Cardiol Therapeutics Inc

Actions
  • Price (USD)2.00
  • Today's Change0.005 / 0.25%
  • Shares traded352.90k
  • 1 Year change+162.53%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 16:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-29.34m
  • Incorporated2017
  • Employees17.00
  • Location
    Cardiol Therapeutics Inc602-2265 Upper Middle Road EastOAKVILLE L6H 0G5CanadaCAN
  • Phone+1 (289) 910-0850
  • Fax+1 (905) 491-6793
  • Websitehttps://www.cardiolrx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.